Plasma

Category

Mount Sinai Licenses SARS-COV-2 Antibody to Sorrento Therapeutics Which Prepares for IND in Anticipation of Phase I Clinical Trial by Q3

Mount Sinai Health System (“Mount Sinai”) and Sorrento Therapeutics (Nasdaq: “SRNE,” “Sorrento”) have inked a deal to investigate an antibody cocktail called COVI-SHIELD™ that potentially can treat COVID-19 patients. This investigational product leverages the work...

University Hospital Ghent Sees Remarkable Results from Administering Convalescent Plasma on Severe COVID-19 Patient

The University Hospital of Ghent recently saw a patient struggling with a severe COVID-19-based infection rapidly improve after receiving a convalescent plasma procedure.   TrialSite News updates the network based on recent news out of the Brussels...

‘Unprecedented Times call for Bold Moves’ as Competitive Plasma Firms Unite to Battle COVID-19

CSL Behring and Takeda Pharmaceutical Company have initiated an alliance bringing together the world’s leading plasma companies to focus on developing and delivering hyperimmune immunoglobulin to help fight the global war on COVID-19. Led by Australian and American...